[3H]bumetanide binding to avian erythrocyte membranes. Correlation with activation and deactivation of Na/K/2Cl cotransport.
The relationship between Na/K/2Cl cotransport activation in duck erythrocytes and binding of the diuretic [3H]bumetanide to isolated membranes from stimulated cells has been assessed. Cotransport was activated by either cAMP-dependent (norepinephrine) or -independent (fluoride, hypertonicity) pathways. Membranes isolated from unstimulated cells possessed no specific bumetanide binding. In the presence of norepinephrine, cotransport and saturable binding rose in parallel, reaching a maximum after 5-7 min. In membranes from maximally stimulated cells the K1/2 and Bmax for bumetanide binding were 100 nM and 1.7 pmol/mg protein, respectively. The diuretic binding properties of these membranes were characteristic of interactions of ligands with the Na/K/2Cl cotransporter: specific binding required the presence of all three cotransported ions (Na, K, and Cl), and the rank order of potency for diuretic competition with bumetanide for binding sites was benzmetanide greater than bumetanide greater than furosemide. The appearance of specific bumetanide binding was also seen in membranes from erythrocytes activated by non-cAMP-dependent stimuli, with an excellent temporal correlation between cotransport activation and diuretic binding. On removal of all stimuli both cotransport and bumetanide binding declined in parallel. Duck erythrocytes treated with norepinephrine in a solution containing 15 mM K+ swell to a new stable cell volume after 60 min, during which time cotransport becomes inoperative. Bumetanide binding to both whole cells and isolated membranes paralleled the decline in cotransport activity. It is concluded that bumetanide binding to isolated membranes faithfully reflects the state of activation of the Na/K/2Cl cotransporter in intact cells under a variety of conditions.
Pewitt
E B
EB
Department of Pharmacological and Physiological Sciences, University of Chicago, Illinois 60637.
Hedge
R S
RS
Palfrey
H C
HC
D000818:Animals; D001665:Binding Sites; D002034:Bumetanide / Q000097:blood*; D002352:Carrier Proteins / Q000097:blood*; D002712:Chlorides / Q000097:blood*; D004232:Diuretics / Q000097:blood*; D004372:Ducks; D004910:Erythrocyte Membrane / Q000187:drug effects / Q000378:metabolism*; D004912:Erythrocytes / Q000187:drug effects / Q000378:metabolism; D005459:Fluorides / Q000494:pharmacology; D006982:Hypertonic Solutions; D007700:Kinetics; D009638:Norepinephrine / Q000494:pharmacology; D011188:Potassium / Q000097:blood*; D011433:Propranolol / Q000494:pharmacology; D012413:Rubidium / Q000097:blood; D012964:Sodium / Q000097:blood*; D028021:Sodium-Potassium-Chloride Symporters
D002352:Carrier Proteins; D002712:Chlorides; D004232:Diuretics; D006982:Hypertonic Solutions; D028021:Sodium-Potassium-Chloride Symporters; D002034:Bumetanide; D012964:Sodium; D011433:Propranolol; D012413:Rubidium; D005459:Fluorides; D011188:Potassium; D009638:Norepinephrine